TRI-SPRINTEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-SPRINTEC (TRI-SPRINTEC).
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation, and increases viscosity of cervical mucus to inhibit sperm penetration.
| Metabolism | Ethinyl estradiol is metabolized by CYP3A4 and undergoes conjugation; norgestimate is metabolized to norelgestromin and levonorgestrel primarily by CYP3A4 and other enzymes. |
| Excretion | Renal: 50% (metabolites); Fecal: 35% (eliminated in bile); unchanged drug <1%. |
| Half-life | Norelgestromin: 28 hours; Ethinyl estradiol: 17 hours. Steady-state achieved within 7 days. |
| Protein binding | Norelgestromin: 97% bound to albumin and SHBG; Ethinyl estradiol: 98% bound to albumin. |
| Volume of Distribution | Norelgestromin: 2.4 L/kg; Ethinyl estradiol: 2.9 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Transdermal: 100% (systemic absorption rate similar to oral). |
| Onset of Action | Transdermal: 48 hours for full contraceptive effect; patch applied weekly. |
| Duration of Action | Contraceptive protection maintained for 7 days of patch wear; resumed after patch-free week. |
| Molecular Weight | 371.51 |
| Action Class | Combination hormonal contraceptive (estrogen-progestin) |
One tablet (0.035 mg ethinyl estradiol / 0.250 mg norgestimate) orally once daily for 21 days, followed by 7 days of placebo tablets. Repeat cycle.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment required for renal impairment. Use with caution in women with severely impaired renal function due to potential estrogen-related fluid retention. |
| Liver impairment | Contraindicated in acute hepatitis, severe cirrhosis, or liver tumors. For mild hepatic impairment (Child-Pugh A), use with caution; no specific dose adjustment. Avoid in moderate to severe impairment. |
| Pediatric use | Not indicated for use before menarche. For post-menarchal adolescents, same dosing as adults (0.035/0.250 mg daily). Ensure adequate bone mineral density and growth monitoring. |
| Geriatric use | Not indicated for post-menopausal women. Contraindicated in women over 35 who smoke due to increased cardiovascular risk. |
| 1st trimester | Contraindicated due to risk of congenital defects (e.g., cardiovascular and limb defects) from sex hormones. Use during early pregnancy poses unacceptable risk. |
| 2nd trimester | Contraindicated. Exposure in second trimester may be associated with adverse fetal outcomes, though less studied; risk of hormonal disruption remains. |
| 3rd trimester | Contraindicated. Use in third trimester can cause fetal harm, including feminization of male fetus and other endocrine effects. |
Clinical note
Comprehensive clinical and safety monograph for TRI-SPRINTEC (TRI-SPRINTEC).
| Placental transfer | Ethinyl estradiol and norgestimate cross the placenta. Studies show detectable levels in fetal serum; degree of transfer is moderate to high. |
| Breastfeeding | Small amounts of ethinyl estradiol and norgestimate pass into breast milk. Use during breastfeeding may reduce milk production and quality. Generally not recommended; alternative contraception advised. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Women over 35 who smoke are strongly advised not to use this product.
| Common Effects | Nausea, Vomiting, Headache, Breast tenderness, Breakthrough bleeding, Spotting, Weight changes, Mood changes, Acne, Fluid retention |
| Serious Effects | Venous thromboembolism (deep vein thrombosis, pulmonary embolism), Arterial thromboembolism (myocardial infarction, stroke), Hepatic adenoma or hepatocellular carcinoma, Hypertension, Gallbladder disease, Cerebral hemorrhage, Retinal thrombosis |
PregnancyHistory of or current thromboembolic disorders (e.g., DVT, PE)Cerebrovascular or coronary artery diseaseKnown or suspected breast cancerUndiagnosed abnormal uterine bleedingLiver tumors (benign or malignant) or active liver diseaseHypersensitivity to any componentSmoking in women over 35 years old
| Precautions | Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction), Hepatic neoplasia (benign and malignant), Elevated blood pressure, Gallbladder disease, Carbohydrate and lipid metabolic effects, Headache/migraine, Irregular bleeding, Depression, Carcinoma of breast and cervix, Ocular lesions |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy category X. Tri-Sprintec (ethinyl estradiol and norgestimate) is contraindicated in pregnancy due to teratogenic effects from sex hormones. First trimester: Increased risk of non-cardiac birth defects, limb reduction defects, and neural tube defects; discontinue immediately if pregnancy occurs. Second and third trimesters: Associated with masculinization of female fetuses (from progestin), urogenital sinus abnormalities, and potential long-term metabolic effects; use during organogenesis carries highest risk. |
| Fetal Monitoring | Monitor for signs of early pregnancy (β-hCG) before initiation and during use. If pregnancy occurs, discontinue immediately and counsel on risks. No routine fetal monitoring required; however, if accidental exposure, consider detailed fetal ultrasound for anomaly detection. |
| Fertility Effects | Suppresses ovulation, impairing fertility during use. After discontinuation, fertility typically returns rapidly within 1-3 months. No permanent negative effects on fertility documented. |
| Food/Dietary | No significant food interactions are reported. Grapefruit juice may moderately increase ethinyl estradiol levels but is not considered clinically relevant. Maintain consistent dietary habits to minimize breakthrough bleeding; avoid drastic changes in grapefruit consumption. |
| Clinical Pearls | Tri-Sprintec is a monophasic combined oral contraceptive containing ethinyl estradiol and norgestimate. The low estrogen dose (0.035 mg) reduces thromboembolic risk relative to higher-dose pills but does not eliminate it. Breakthrough bleeding is most common in the first 3 months. Concomitant use with potent CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease contraceptive efficacy; consider backup barrier methods during such co-administration. If a patient vomits within 3-4 hours of pill intake, repeat the dose. Prescribe for patients with migraine without aura only if under age 35; avoid in migraine with aura due to stroke risk. |
| Patient Advice | Take one pill daily at the same time each day to maintain hormone levels and prevent ovulation. · If you miss a pill by less than 12 hours, take it immediately and continue on schedule. If more than 12 hours, use backup contraception like condoms for 7 days and follow the package insert for missed-dose instructions. · Common side effects include nausea, headache, breast tenderness, and spotting between periods, which usually improve after 2-3 cycles. · This medication does not protect against HIV or other sexually transmitted infections; use condoms for STI prevention. · Do not smoke while taking this pill due to increased risk of serious cardiovascular events, especially if over 35 years old. · Report immediately any signs of a blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache. |